Liver transplantation for patients with viral hepatitis

Area of Science:

• Hepatology
• Transplant Surgery
• Infectious Diseases

Background:

• End-stage viral hepatitis is a primary reason for liver transplantation.
• Hepatitis recurrence post-transplant significantly reduces recipient survival.
• Hepatitis B recurrence is marked by positive HBsAg; Hepatitis C by positive HCV-RNA.

Purpose of the Study:

• To review factors contributing to viral hepatitis recurrence after liver transplantation.
• To evaluate therapeutic strategies for preventing post-transplant hepatitis recurrence.

Main Methods:

• Literature review of studies on viral hepatitis recurrence post-liver transplant.
• Analysis of risk factors including hepatitis type, patient ethnicity, and immunosuppressive protocols.
• Assessment of prophylactic treatments like hepatitis B immune globulin (HBIg) and antiviral agents (lamivudine, ribavirin).

Main Results:

• Hepatitis recurrence is a major threat to liver transplant recipient survival.
• Factors influencing recurrence include hepatitis characteristics, ethnicity, and immunosuppression.
• High-dose, long-term combination therapy with HBIg and novel antivirals demonstrates efficacy.

Conclusions:

• Preventing viral hepatitis recurrence is crucial for improving liver transplant outcomes.
• Combination therapy involving HBIg and agents like lamivudine offers a promising strategy.
• Further research into optimal prophylactic regimens is warranted.